RU2664429C2 - Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA - Google Patents

Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA Download PDF

Info

Publication number
RU2664429C2
RU2664429C2 RU2014128500A RU2014128500A RU2664429C2 RU 2664429 C2 RU2664429 C2 RU 2664429C2 RU 2014128500 A RU2014128500 A RU 2014128500A RU 2014128500 A RU2014128500 A RU 2014128500A RU 2664429 C2 RU2664429 C2 RU 2664429C2
Authority
RU
Russia
Prior art keywords
amount
acid
dpa
levels
epa
Prior art date
Application number
RU2014128500A
Other languages
English (en)
Russian (ru)
Other versions
RU2014128500A (ru
Inventor
Тимоти Дж. МЭЙНС
Бернардус Н М МАЧИЛС
Бхарат М. МЕХТА
Джеральд УАЙСЛЕР
Майкл ДЭВИДСОН
Питер Ральф ВУД
Original Assignee
Омтера Фармасьютикалс, Инк.
Крисалис Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48744082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2664429(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Омтера Фармасьютикалс, Инк., Крисалис Фарма Аг filed Critical Омтера Фармасьютикалс, Инк.
Publication of RU2014128500A publication Critical patent/RU2014128500A/ru
Application granted granted Critical
Publication of RU2664429C2 publication Critical patent/RU2664429C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Materials For Photolithography (AREA)
RU2014128500A 2012-01-06 2013-01-04 Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA RU2664429C2 (ru)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201261583796P 2012-01-06 2012-01-06
US61/583,796 2012-01-06
US201261664047P 2012-06-25 2012-06-25
US61/664,047 2012-06-25
US201261669940P 2012-07-10 2012-07-10
US61/669,940 2012-07-10
US201261680622P 2012-08-07 2012-08-07
US61/680,622 2012-08-07
US201261710517P 2012-10-05 2012-10-05
US61/710,517 2012-10-05
US201261713388P 2012-10-12 2012-10-12
US61/713,388 2012-10-12
PCT/US2013/020398 WO2013103902A1 (en) 2012-01-06 2013-01-04 Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018116572A Division RU2018116572A (ru) 2012-01-06 2013-01-04 Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA

Publications (2)

Publication Number Publication Date
RU2014128500A RU2014128500A (ru) 2016-02-27
RU2664429C2 true RU2664429C2 (ru) 2018-08-17

Family

ID=48744082

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014128500A RU2664429C2 (ru) 2012-01-06 2013-01-04 Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA
RU2018116572A RU2018116572A (ru) 2012-01-06 2013-01-04 Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2018116572A RU2018116572A (ru) 2012-01-06 2013-01-04 Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA

Country Status (35)

Country Link
US (5) US9050308B2 (enExample)
EP (2) EP3348262A1 (enExample)
JP (3) JP6399655B2 (enExample)
KR (2) KR102153245B1 (enExample)
CN (3) CN104321055A (enExample)
BR (1) BR112014016788A8 (enExample)
CA (1) CA2860512C (enExample)
CL (1) CL2014001803A1 (enExample)
CO (1) CO7061070A2 (enExample)
CY (1) CY1120663T1 (enExample)
DK (1) DK2800563T3 (enExample)
DO (1) DOP2014000159A (enExample)
EC (1) ECSP14012527A (enExample)
ES (1) ES2685703T3 (enExample)
HK (1) HK1251457A1 (enExample)
HR (1) HRP20181418T1 (enExample)
HU (1) HUE039659T2 (enExample)
IL (3) IL233517A (enExample)
IN (1) IN2014DN06125A (enExample)
LT (1) LT2800563T (enExample)
MX (1) MX358319B (enExample)
MY (1) MY165048A (enExample)
NZ (1) NZ626699A (enExample)
PE (1) PE20142459A1 (enExample)
PH (2) PH12014501553B1 (enExample)
PL (1) PL2800563T3 (enExample)
PT (1) PT2800563T (enExample)
RS (1) RS57777B1 (enExample)
RU (2) RU2664429C2 (enExample)
SG (2) SG11201403805WA (enExample)
SI (1) SI2800563T1 (enExample)
SM (1) SMT201800519T1 (enExample)
UA (1) UA114615C2 (enExample)
WO (1) WO2013103902A1 (enExample)
ZA (1) ZA201405765B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
SG11201403805WA (en) * 2012-01-06 2014-08-28 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
AR095182A1 (es) * 2012-05-07 2015-09-30 Omthera Pharmaceuticals Inc Composiciones de estatinas y ácidos grasos omega-3
EP2861227A4 (en) * 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
JP2016500055A (ja) * 2012-10-23 2016-01-07 ディーキン・ユニバーシティー トリグリセリドを低減させる方法
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US9452151B2 (en) * 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
WO2015011724A2 (en) 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
WO2015024055A1 (en) * 2013-08-20 2015-02-26 Deakin University Separation of omega-3 fatty acids
MX2016004487A (es) * 2013-10-30 2016-11-10 Banner Life Sciences Llc Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados.
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
EP3140316A1 (en) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
WO2015185698A1 (en) 2014-06-04 2015-12-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
EP3157936B1 (en) 2014-06-18 2018-10-17 Thetis Pharmaceuticals LLC Mineral amino-acid complexes of active agents
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
WO2016069446A1 (en) * 2014-10-28 2016-05-06 Omthera Pharmaceuticals Inc Methods for modulating plasma levels of lipoproteins
WO2016073335A1 (en) * 2014-11-05 2016-05-12 Omthera Pharmaceuticals Inc. Methods of treatment
US20160192126A1 (en) * 2014-12-31 2016-06-30 Silver Spring Networks, Inc. System and method for tracking a device
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
WO2016178066A1 (en) * 2015-05-01 2016-11-10 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
JP2018524274A (ja) 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
JP2018520197A (ja) 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
CN113230244A (zh) 2015-12-18 2021-08-10 艾菲穆恩有限公司 包含15-hepe的组合物及其使用方法
US10263794B2 (en) * 2016-05-19 2019-04-16 Linear Technology Corporation Maintain power signature controller at power interface of PoE or PoDL system
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
GB201611920D0 (en) 2016-07-08 2016-08-24 Astrazeneca Ab Pharmaceutical compositions
HUE063275T2 (hu) 2017-05-16 2024-01-28 Ability Pharmaceuticals S A Gyógyszerészeti kombináció rákbetegség kezelésére
WO2019008101A1 (en) 2017-07-06 2019-01-10 Evonik Technochemie Gmbh ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS
CN111032032B (zh) 2017-08-15 2024-01-02 赢创运营有限公司 具有高活性成分含量的ω-3脂肪酸氨基酸盐的片剂
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions
US20220280387A1 (en) 2019-08-08 2022-09-08 Evonik Operations Gmbh Down streaming process for the production of polyunsaturated fatty acid salts
US20220287345A1 (en) 2019-08-08 2022-09-15 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502077A (en) * 1988-08-11 1996-03-26 Norsk Hydro A.S. Fatty acid composition
RU2332445C2 (ru) * 2003-07-09 2008-08-27 Джей-Ойл Миллз, Инк. Антиоксидантная жировая или масляная композиция со стабильным вкусом
US20110034555A1 (en) * 2009-06-15 2011-02-10 Amarin Pharma , Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735512A (en) 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
US4377526A (en) 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
BR8803255A (pt) 1981-11-10 1990-02-06 Century Lab Inc Processo de extracao e purificacao de acidos graxos poli-insaturados de fontes naturais
JPS59157018A (ja) 1983-02-27 1984-09-06 Furointo Sangyo Kk 新規なる被覆含油カプセル剤形
JPS59225115A (ja) 1983-06-06 1984-12-18 Ota Seiyaku Kk 青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル
JPS61126016A (ja) 1984-11-22 1986-06-13 Toagosei Chem Ind Co Ltd 不飽和脂肪酸を内相物としたマイクロカプセル
EP0347509A1 (en) 1988-06-21 1989-12-27 Century Laboratories Inc. A process of extraction and purification of polyunsaturated fatty acids from natural sources
CH669208A5 (fr) 1986-12-17 1989-02-28 Nestle Sa Procede de fractionnement en continu d'un melange d'acides gras.
US5243046A (en) 1986-12-17 1993-09-07 Nestec S.A. Process for the continuous fractionation of a mixture of fatty acids
DE3863678D1 (de) 1987-04-27 1991-08-22 Efamol Holdings Lithiumsalze enthaltende pharmazeutische zubereitungen.
IT1205043B (it) 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
ZA885473B (en) 1987-08-07 1989-03-29 Century Lab Inc Free fatty acids for treatment of diabetes mellitus
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
NL9201438A (nl) 1992-08-11 1994-03-01 Prospa Bv Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
DE69420124T2 (de) 1993-01-15 2000-03-02 Abbott Laboratories, Abbott Park Strukturierte lipide
AU676910B2 (en) 1993-04-29 1997-03-27 Norsk Hydro A.S Processes for chromatographic fractionation of fatty acids and their derivatives
JPH0753356A (ja) 1993-08-16 1995-02-28 Morishita Jintan Kk 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法
US5767156A (en) 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
IT1264987B1 (it) 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
US5494684A (en) 1994-02-23 1996-02-27 Bar-Ilan University Plant protection from infection by Phytophthora infestans using fish oil
GB9404483D0 (en) 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
RU2127115C1 (ru) 1994-03-28 1999-03-10 Владимир Константинович Гаврисюк Смесь омега-3 полиненасыщенных жирных кислот
DE69417726T2 (de) 1994-05-09 1999-08-19 Societe Des Produits Nestle S.A. Verfahren zur Herstellung eines Konzentrates von Estern von mehrfach ungesättigten Fettsäuren
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JPH08100191A (ja) * 1994-09-30 1996-04-16 Nisshin Flour Milling Co Ltd 高度不飽和脂肪酸またはそのエステルの精製方法
NL9401743A (nl) 1994-10-20 1996-06-03 Prospa Bv Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
GB2300807B (en) 1995-05-15 1999-08-18 Tillotts Pharma Ag Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
AU2738497A (en) 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
JPH1095744A (ja) * 1996-09-20 1998-04-14 Nof Corp 高度不飽和脂肪酸又はそのアルキルエステルの製造方法
DE69622722T2 (de) 1996-11-20 2003-02-27 N.V. Nutricia, Zoetermeer Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
GB9701705D0 (en) 1997-01-28 1997-03-19 Norsk Hydro As Purifying polyunsatured fatty acid glycerides
EP0973934A4 (en) 1997-02-25 2003-02-05 Genzyme Transgenics Corp TRANSGEN PRODUCED NON-SECRETED PROTEINS.
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
ATE497384T1 (de) 1997-12-10 2011-02-15 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
NO312973B1 (no) 1999-02-17 2002-07-22 Norsk Hydro As Lipase-katalysert forestring av marine oljer
US7112609B2 (en) 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
JP2001054396A (ja) 1999-06-08 2001-02-27 Nippon Suisan Kaisha Ltd リパーゼによる高度不飽和脂肪酸含有油脂の製造方法
AU5319499A (en) 1999-07-22 2001-02-13 Ivan L. Cameron Fatty acids to minimize cancer therapy side effects
NO310113B1 (no) 1999-08-11 2001-05-21 Norsk Hydro As Fremgangsmåte for utvinning av flerumettede fettsyrer fra ureakomplekser
EP1211955A1 (en) 1999-08-30 2002-06-12 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
DE60045101D1 (de) 1999-08-31 2010-11-25 Chugai Pharmaceutical Co Ltd Weichkapseln
EP1106072B1 (en) 1999-12-10 2005-11-30 Loders Croklaan B.V. Palmitoleic acid and its use in foods
AU2634101A (en) 2000-01-06 2001-07-16 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
ES2246769T3 (es) 2000-05-22 2006-03-01 Pro Aparts - Investimentos E Consultoria Lda Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico.
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
GB0016452D0 (en) 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
EP1178103A1 (en) 2000-08-02 2002-02-06 Dsm N.V. Purifying crude pufa oils
KR20010008387A (ko) 2000-11-30 2001-02-05 이성권 결정화방법을 이용한 고순도 불포화지방산의 분리 정제 방법
DK1997498T3 (da) 2001-06-18 2012-07-30 Neptune Technologies & Bioressources Inc Krillekstrakter til forebyggelse og/eller behandling af kardiovaskulære sygdomme
CN1197564C (zh) * 2001-09-30 2005-04-20 中国药品生物制品检定所 海狗油在制备治疗脂代谢紊乱药物中的应用
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
GB2385852A (en) 2002-02-27 2003-09-03 Rothamsted Ex Station Delta 6-desaturases from Primulaceae
WO2003082339A1 (en) 2002-03-22 2003-10-09 Doc's Guide, Inc. Multivitamin and mineral nutritional supplement
DE10214005A1 (de) 2002-03-27 2003-10-09 Volker Bartz Blutfettsenker zur oralen Einnahme, bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA (Eicosapentaensäure) und DHA (Docosapentaensäure) und Pektin und/oder Guar als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente
ITMI20020731A1 (it) 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
NZ518504A (en) 2002-04-22 2005-05-27 Ind Res Ltd Use of near-critical fluids in the separation of saturated and mono-unsaturated fatty acids from urea-containing solutions
EP2295529B2 (en) 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
SE0202188D0 (sv) 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
NO319194B1 (no) 2002-11-14 2005-06-27 Pronova Biocare As Lipase-katalysert forestringsfremgangsmate av marine oljer
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
WO2004056370A1 (en) 2002-12-20 2004-07-08 Pronova Biocare As Use of a fatty acid composition for treatment of male infertility
CA2524863A1 (en) 2003-05-05 2004-11-18 Denofa As Fish oils with an altered fatty acid profile, method of producing same and their use
US6846942B2 (en) 2003-05-20 2005-01-25 David Rubin Method for preparing pure EPA and pure DHA
US7759507B2 (en) 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
ITMI20032247A1 (it) 2003-11-19 2005-05-20 Tiberio Bruzzese Interazione di derivati polari di composti insaturi con substrati inorganici
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US20070265341A1 (en) 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
WO2006004438A1 (en) 2004-07-05 2006-01-12 Otago Innovation Limited Hoki fish liver oil, fractions thereof and therapeutic uses
RU2388490C2 (ru) 2004-07-19 2010-05-10 Тиа Медика Ас Композиция, содержащая растительный или рыбий жир, и соединения, содержащие неокисляющиеся структурные элементы жирных кислот
KR20070054637A (ko) 2004-07-19 2007-05-29 티아 메디카 에이에스 식물유 및/또는 어유 및 비-산화성 지방산 구성요소를포함하는 조성물
AU2005271413A1 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
KR20070052760A (ko) 2004-08-06 2007-05-22 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 페노피브레이트 제제 및 관련된 치료방법
WO2007130713A1 (en) 2006-02-01 2007-11-15 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
WO2007130714A1 (en) 2006-02-01 2007-11-15 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
AU2005282241B2 (en) 2004-09-08 2011-03-03 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
WO2006036983A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
DE102004062141A1 (de) 2004-12-23 2006-07-06 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Verfahren zur Herstellung eines Rohöls aus Gemischen von Mikroorganismen und Pflanzen, das so hergestellte Öl sowie die spezifischen Verwendungen des so hergestellten und gegebenenfalls zusätzlich raffinierten Öls
CA2594781A1 (en) 2005-01-24 2006-07-27 Pronova Biocare As Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases
EP1858352B1 (en) 2005-02-18 2013-06-05 Delante Health AS A composition comprising a powder containing microencapsulated polyunsaturated long-chain esterified fatty acids distributed in an effervescent base
US20060211763A1 (en) 2005-03-08 2006-09-21 Abdel Fawzy Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof
DE102005013779A1 (de) 2005-03-22 2006-09-28 Basf Plant Science Gmbh Verfahren zur Herstellung von mehrfach ungesättigten C20- und C22-Fettsäuren mit mindestens vier Doppelbindungen in transgenen Pflanzen
WO2006102896A2 (en) 2005-03-29 2006-10-05 Aalborg Universitet A process to concentrate ω3-pufa from fish oil by selective hydrolysis using cutinase immobilized on zeolite nay
KR100539357B1 (ko) 2005-04-11 2005-12-28 동부한농화학 주식회사 불포화 지방산의 제조방법
JP2008540394A (ja) 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
US8034391B2 (en) 2005-07-01 2011-10-11 Martek Biosciences Corporation Polyunsaturated fatty acid-containing oil product and uses and production thereof
US20070020340A1 (en) 2005-07-25 2007-01-25 David Rubin Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
JP2009515816A (ja) 2005-08-04 2009-04-16 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法
ITMI20051560A1 (it) 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
US20070134493A1 (en) 2005-12-08 2007-06-14 Kanji Meghpara Compositions and capsules with stable hydrophilic layers
CA2634139C (en) 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
FR2896172B1 (fr) 2006-01-17 2008-10-10 Polaris Soc Par Actions Simpli Nouveau procede de stabilisation des acides gras polyinsatures et les compositions ainsi obtenus.
AR059376A1 (es) 2006-02-21 2008-03-26 Basf Plant Science Gmbh Procedimiento para la produccion de acidos grasos poliinsaturados
DE102006008030A1 (de) 2006-02-21 2007-08-23 Basf Plant Science Gmbh Verfahren zur Herstellung von mehrfach ungesättigten Fettsäuren
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
US8003813B2 (en) 2006-06-27 2011-08-23 Pos Pilot Plant Corporation Process for separating saturated and unsaturated fatty acids
KR100684641B1 (ko) 2006-07-25 2007-02-22 주식회사 일신웰스 유지 조성물, 이를 함유하는 식품 및 건강보조식품
US20090304784A1 (en) 2006-07-28 2009-12-10 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
KR100758664B1 (ko) 2006-08-16 2007-09-13 (주)케비젠 불포화지방산 함유 마이크로캡슐의 제조방법, 이 방법에의해 제조된 마이크로캡슐 및 이를 포함하는 제품
CN101194913A (zh) * 2006-12-05 2008-06-11 张金生 治疗血脂偏高的天然海豹油浓缩生物制剂及其制备工艺
AU2008205325B2 (en) 2007-01-10 2013-09-12 Dsm Nutritional Products Ag Vegetarian microcapsules
WO2008088808A1 (en) 2007-01-16 2008-07-24 Reliant Pharmaceuticals, Inc. Treatment with non-steroidal anti-inflammatory drugs and omega-3 fatty acids, and a combination product thereof
US20110190389A1 (en) 2007-02-20 2011-08-04 Linda Arterburn Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
CA2677670C (en) 2007-03-20 2010-08-03 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
EP2147088A4 (en) 2007-04-26 2010-05-05 Patrick Adlercreutz FERTILIZED MILK OILS COMPRISING MULTIPLE-UNSATURATED FATTY ACIDS, COMPRISING EICOSAPENTAIC ACID (EPA) AND DOCOSAHEXAIC ACID (DHA), AND MANUFACTURING METHOD THEREFOR
CA2692394A1 (en) 2007-07-06 2009-01-15 Seth J. Baum Fatty acid compositions and methods of use
CL2008002020A1 (es) 2007-07-12 2008-11-14 Ocean Nutrition Canada Ltd Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
WO2009014452A1 (en) 2007-07-25 2009-01-29 Epax As Omega-3 fatty acid fortified composition
WO2009017102A1 (ja) 2007-07-30 2009-02-05 Nippon Suisan Kaisha, Ltd. Epa濃縮油およびdha濃縮油の製造方法
WO2009020406A1 (en) 2007-08-07 2009-02-12 Granate Seed Limited Methods of making lipid substances, lipid substances made thereby and uses thereof
WO2009028457A1 (ja) 2007-08-29 2009-03-05 Shinshu University 非アルコール性脂肪肝炎治療薬
DE102007055344A1 (de) 2007-11-19 2009-05-20 K. D. Pharma Bexbach Gmbh Neue Verwendung von Omega-3-Fettsäure(n)
UA102477C2 (en) 2008-01-10 2013-07-10 Такеда Фармасьютикал Компани Лимитед Capsule composition
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
MX2010012482A (es) 2008-05-15 2010-12-01 Pronova Biopharma Norge As Proceso para aceite de kril.
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US20100062057A1 (en) 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
PT3196313T (pt) 2008-10-02 2021-04-13 Gonzalez Ramon Nieves Extrato de microalgas contendo ácidos graxos poli-saturados omega3 e método para extrair óleo de microrganismos
CA2742227C (en) 2008-10-31 2017-01-24 Lipid Pharmaceuticals Ehf. The use of fatty acid compositions as laxatives
ES2769926T3 (es) 2009-02-10 2020-06-29 Amarin Pharmaceuticals Ie Ltd Ester etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
CN101822651A (zh) * 2009-03-05 2010-09-08 Dpa工业公司 可咀嚼胶囊及其制备方法
AU2010222648B2 (en) 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
WO2010118761A1 (en) 2009-04-17 2010-10-21 Eolas Science Limited Compositions rich in omega-3 fatty acids with a low content in phytanic acid
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
KR20120015335A (ko) 2009-05-01 2012-02-21 마이크로파마 리미티드 퇴행성 질환의 예방 및 치료를 위한 박테리아 조성물
SG178948A1 (en) 2009-09-01 2012-04-27 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011048493A1 (en) 2009-10-23 2011-04-28 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
RU2009145010A (ru) 2009-12-04 2011-06-20 Общество с ограниченной ответственностью (ООО) "Аббифарм" (RU) Композиция омега-3 и омега-6 полиненасыщенных жирных кислот
WO2011095284A1 (de) 2010-02-02 2011-08-11 Cognis Ip Management Gmbh Anreicherung von mehrfach ungesättigten fettsäuren
GB201006204D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
CN103282474A (zh) 2010-04-22 2013-09-04 纳幕尔杜邦公司 从微生物生物质中获得包含多不饱和脂肪酸的组合物的方法
US9476008B2 (en) 2010-06-25 2016-10-25 Epax As Process for separating polyunsaturated fatty acids from long chain unsaturated or less saturated fatty acids
EP2613766A4 (en) 2010-09-08 2014-04-09 Pronova Biopharma Norge As COMPOSITIONS COMPRISING AN OIL MIXTURE CONSISTING OF FATTY ACIDS COMPRISING EPA AND DHA AS FREE ACID, SURFACTANT AND STATIN
KR101904392B1 (ko) 2010-09-24 2018-10-05 프로노바 바이오파마 너지 에이에스 오메가-3 지방산을 농축하기 위한 공정
WO2012083034A1 (en) 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
WO2012087153A1 (en) 2010-12-23 2012-06-28 Marine Bioproducts As Enrichment of marine oils with omega-3 polyunsaturated fatty acids by lipase-catalysed hydrolysis
EP2476425B1 (en) 2011-01-14 2014-03-19 Visiotact Pharma Composition comprising OPC and Omega-3 for preventing and/or inhibiting the development of diabetic retinopathy
JP2014505729A (ja) 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤（アゼチジノン）およびω３脂肪酸（ＥＰＡ、ＤＨＡ、ＤＰＡ）
CA2827561A1 (en) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
EP2675446A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
WO2012112531A1 (en) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
WO2012112520A1 (en) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
WO2012112902A1 (en) 2011-02-18 2012-08-23 Martek Biosciences Corporation Methods of preparing free polyunsaturated fatty acids
US20140051877A1 (en) 2011-04-28 2014-02-20 Nandakishore Jeevanrao Duragkar Eicosapentaenoic acid (epa) as polyunsaturated free fatty acid in its directly compressible powder form and process of isolation thereof
CN102311868B (zh) 2011-04-29 2017-05-24 塞拉斯有限责任公司 一种无溶剂提取富含磷脂和中性油脂的磷虾油的方法
US8697676B2 (en) 2011-06-15 2014-04-15 Ronald E Rosedale Omega-3 fatty acid nutriceutical composition and optimization method
WO2013040507A1 (en) 2011-09-15 2013-03-21 Omthera Pharmaceuticals, Inc. Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
JP2015501426A (ja) 2011-10-21 2015-01-15 オムセラ・ファーマシューティカルズ・インコーポレイテッド 注意欠陥多動障害を処置するまたは予防する方法および組成物
WO2013063067A1 (en) * 2011-10-24 2013-05-02 Stable Solutions Llc Enriched injectable emulsion containing selected fatty acid triglycerides
SG11201403805WA (en) 2012-01-06 2014-08-28 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
AU2013240427B2 (en) 2012-03-30 2017-08-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
AR095182A1 (es) 2012-05-07 2015-09-30 Omthera Pharmaceuticals Inc Composiciones de estatinas y ácidos grasos omega-3
US20140194512A1 (en) 2012-06-17 2014-07-10 Matinas Biopharma, Inc. Compositions comprising docosapentaenoic acid and methods of use
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
WO2016069446A1 (en) 2014-10-28 2016-05-06 Omthera Pharmaceuticals Inc Methods for modulating plasma levels of lipoproteins
WO2016073335A1 (en) 2014-11-05 2016-05-12 Omthera Pharmaceuticals Inc. Methods of treatment
WO2016130417A1 (en) 2015-02-11 2016-08-18 Omthera Pharmaceuticals Inc Omega-3 fatty acid prodrug compounds and uses thereof
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502077A (en) * 1988-08-11 1996-03-26 Norsk Hydro A.S. Fatty acid composition
RU2332445C2 (ru) * 2003-07-09 2008-08-27 Джей-Ойл Миллз, Инк. Антиоксидантная жировая или масляная композиция со стабильным вкусом
US20110034555A1 (en) * 2009-06-15 2011-02-10 Amarin Pharma , Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy

Also Published As

Publication number Publication date
PH12015502307B1 (en) 2017-04-10
IN2014DN06125A (enExample) 2015-08-14
CY1120663T1 (el) 2019-12-11
US20130209556A1 (en) 2013-08-15
BR112014016788A2 (pt) 2017-06-13
JP6626857B2 (ja) 2019-12-25
JP6399655B2 (ja) 2018-10-03
PL2800563T3 (pl) 2018-12-31
KR20190119658A (ko) 2019-10-22
US10117844B2 (en) 2018-11-06
JP2020045358A (ja) 2020-03-26
JP2017214392A (ja) 2017-12-07
CA2860512A1 (en) 2013-07-11
LT2800563T (lt) 2018-10-25
US20150320715A1 (en) 2015-11-12
PH12014501553A1 (en) 2014-10-08
JP2015503590A (ja) 2015-02-02
CN108524483A (zh) 2018-09-14
DK2800563T3 (en) 2018-10-08
US9050309B2 (en) 2015-06-09
US9050308B2 (en) 2015-06-09
IL233517A0 (en) 2014-08-31
PH12015502307A1 (en) 2017-04-10
HK1251457A1 (en) 2019-02-01
CL2014001803A1 (es) 2015-01-30
NZ626699A (en) 2017-03-31
ZA201405765B (en) 2016-05-25
EP2800563A1 (en) 2014-11-12
KR20140135695A (ko) 2014-11-26
EP2800563B1 (en) 2018-07-11
US20150004224A1 (en) 2015-01-01
BR112014016788A8 (pt) 2017-07-04
IL252084B (en) 2019-05-30
MX358319B (es) 2018-08-14
MY165048A (en) 2018-02-28
RU2018116572A (ru) 2018-10-23
IL266231A (en) 2019-06-30
IL252084A0 (en) 2017-07-31
EP2800563A4 (en) 2015-06-17
PE20142459A1 (es) 2015-01-23
US20130177643A1 (en) 2013-07-11
SG10201701004RA (en) 2017-04-27
SMT201800519T1 (it) 2018-11-09
WO2013103902A1 (en) 2013-07-11
IL266231B (en) 2020-08-31
CN104321055A (zh) 2015-01-28
ES2685703T3 (es) 2018-10-10
DOP2014000159A (es) 2014-12-15
MX2014008309A (es) 2015-04-13
HK1202073A1 (en) 2015-09-18
RS57777B1 (sr) 2018-12-31
EP3348262A1 (en) 2018-07-18
RU2014128500A (ru) 2016-02-27
SI2800563T1 (sl) 2018-11-30
CO7061070A2 (es) 2014-09-19
IL233517A (en) 2017-05-29
PH12014501553B1 (en) 2014-10-08
KR102153245B1 (ko) 2020-09-08
HUE039659T2 (hu) 2019-01-28
KR102153143B1 (ko) 2020-09-08
CN107050457A (zh) 2017-08-18
SG11201403805WA (en) 2014-08-28
PT2800563T (pt) 2018-11-07
ECSP14012527A (es) 2015-09-30
HRP20181418T1 (hr) 2018-11-30
US20190029985A1 (en) 2019-01-31
UA114615C2 (uk) 2017-07-10
CA2860512C (en) 2019-02-05

Similar Documents

Publication Publication Date Title
RU2664429C2 (ru) Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA
Davidson Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid
US20130095179A1 (en) Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
US20110178105A1 (en) Clinical benefits of eicosapentaenoic acid in humans
JP2014024859A (ja) Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸
JP6469261B2 (ja) 多価不飽和遊離脂肪酸を含むミリカプセル製剤
AU2013201793B2 (en) DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
HK1261434A1 (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
HK1239541A1 (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
HK1202073B (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
WO2016069446A1 (en) Methods for modulating plasma levels of lipoproteins
AU2015203404A1 (en) DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Silldorff et al. Reducing cardiovascular risk-are omega 3 fatty acids the solution?
JP2016500055A (ja) トリグリセリドを低減させる方法